Efficacy trial of pipobroman in essential thrombocythemia: A study of 24 patients

E. Brusamolino, A. Canevari, L. Salvaneschi, S. Merante, C. Bernasconi

Research output: Contribution to journalArticlepeer-review


Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120). Plateletpheresis was not done. Hematologic complete response (platelet count <450 x 109/L for 3 consecutive months) was achieved in 92% of the cases, in a median time of 12 weeks (range, 2-22). However, continuous low-dose maintenance therapy with PB was necessary to avoid recurrences of the disease. Major thrombocythemia-related complications were observed in 20% of the cases; the 5-year overall and complication-free survival rates were 92% and 75%, respectively. No acute or chronic toxicity was observed; no drug-induced amenorrhea and subsequent acute leukemia occurred. PB does appear to be efficacious in essential thrombocythemia; however, the evaluation of its leukemogenic risk will await further experience.

Original languageEnglish
Pages (from-to)1339-1342
Number of pages4
JournalCancer Treatment Reports
Issue number11
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Efficacy trial of pipobroman in essential thrombocythemia: A study of 24 patients'. Together they form a unique fingerprint.

Cite this